Journal article
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
Abstract
BACKGROUND: The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally administered interleukin-23-receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.
METHODS: In this phase 2 dose-finding trial, we randomly assigned …
Authors
Bissonnette R; Pinter A; Ferris LK; Gerdes S; Rich P; Vender R; Miller M; Shen Y-K; Kannan A; Li S
Journal
The New England Journal of Medicine, Vol. 390, No. 6, pp. 510–521
Publisher
Massachusetts Medical Society
Publication Date
February 8, 2024
DOI
10.1056/nejmoa2308713
ISSN
0028-4793